Hearing aid company Eargo and Hearx combine, securing a $100 million investment to form a single over-the-counter hearing solution business.
In the dynamic world of digital health and medical devices, the merger of Eargo, Hearx, and Lexie Hearing has created a formidable player in the over-the-counter (OTC) hearing aid industry. This strategic union, backed by a $100 million investment from Patient Square Capital, is poised to revolutionise the OTC hearing aid market [2].
**Background and Market Context**
Before the merger, Eargo was a trailblazer in the field, offering nearly invisible hearing aids designed for mild to moderate hearing loss. The company, based in San Jose, California, had raised over $231 million [1]. The OTC hearing aid market has experienced significant growth since the Food and Drug Administration legalised OTC hearing aids in late 2022, expanding retail pharmacy and e-commerce sales channels [3]. Rechargeable lithium-ion battery hearing aids, a key feature of Eargo devices, account for approximately 80% of U.S. unit sales, driving user adoption and convenience [3].
**Strategic Positioning**
By merging with Hearx and Lexie Hearing, LXE Hearing has a broad product offering, strong branding, and extensive distribution networks across both physical and digital channels [2][5]. Lexie, another notable OTC hearing aid brand, offers models priced between $499 and $999 and is sold through major retailers and online platforms. The combined company aims to capitalise on this diverse product range and widespread market access.
**Market Size and Growth**
The overall hearing aids market is projected to reach around $10.12 billion in 2025 and grow to nearly $13 billion by 2030, with a CAGR of 4.9% to 6.9% [1][3]. The OTC segment, a key growth driver within this industry, is expected to show robust growth.
**Innovation and Competitiveness**
LXE Hearing, alongside industry giants such as Philips, Cochlear, and Phonak, is recognised as a leader in the smart hearing solutions market [1]. As part of the merger, Seline Van der Wat and Brian Maguire of Hearx, and Tim Trine of Eargo, have joined LXE's C-suite, bringing valuable expertise to the table.
**Recent Developments**
As a private company, Eargo launched two new OTC hearing aids, Eargo SE and Link by Eargo. Link by Eargo is the first earbud-style, OTC hearing aid with Bluetooth 5.3. In another significant move, Lexie was named the number one hearing aid brand in the U.S. by industry data company Circana from August 2023 to July 2024.
With its strong financial backing, innovative products, and strategic positioning, LXE Hearing is well-placed to shape the future of the OTC hearing aid market, promising exciting times ahead for this rapidly expanding $13+ billion segment.
- The Food and Drug Administration's approval of over-the-counter (OTC) hearing aids has fueled significant growth in the OTC hearing aid market, opening up retail pharmacy and e-commerce sales channels.
- The merger of Eargo, Hearx, and Lexie Hearing has created a significant player in the OTC hearing aid industry, backed by a $100 million investment from Patient Square Capital.
- The combined company, now known as LXE Hearing, boasts a diverse product range, strong branding, and extensive distribution networks, both physical and digital.
- The hearing aids market is projected to reach approximately $10.12 billion in 2025 and grow to nearly $13 billion by 2030, with the OTC segment driving a significant portion of this growth.
- In the competitive landscape of the smart hearing solutions market, LXE Hearing, along with industry titans such as Philips, Cochlear, and Phonak, is considered a leader.
- As part of the recent merger, key executives from Hearx and Eargo, Seline Van der Wat, Brian Maguire, and Tim Trine, have joined LXE's C-suite, bringing valuable expertise and innovation to the table.
- Recognized as a top player, LXE Hearing, with its strategic positioning, innovative products, and robust financial backing, is poised to shape the future of the OTC hearing aid market, making the health-and-wellness and medtech sectors eager to follow the news in this dynamic industry.
